Compare Abeona Therapeutics Inc (ABEO) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs JPMorgan Ultra Short Income ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while JPMorgan Ultra Short Income ETF trades at $50.44. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | JPST | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $7.23 | $50.78 |
52-Week Low | $4.17 | $50.40 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
JPST, the JPMorgan Ultra-Short Income ETF, trades at $50.45, up 0.06% on the day. The technical outlook is bearish based on moving averages, with oscillators neutral. Recent news highlights its role as a cash alternative, with institutional inflows and consistent monthly dividends. The fund focuses on high-quality, short-term bonds for income and capital preservation.
The outlook remains stable given its low-risk profile, offering a yield advantage over savings accounts. Risks include interest rate sensitivity and credit spread changes. Wall Street sentiment is positive for risk-averse investors seeking short-term income, though technical indicators suggest near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
